Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Those with GDM in current pregnancy using a Dexcom Continuous Glucose Monitoring (CGM) are eligible for enrollment. Participants use their CGM as usual during pregnancy and wear one sensor postpartum. They have their standard of care OGTT performed at around 6 weeks. They then complete a remote questionnaire after OGTT.

Inclusion Criteria:

• Diagnosis of gestational diabetes during current pregnancy
• age 18 or older
• prescribed Dexcom G7

Exclusion Criteria:

• Pregestational diabetes
• known skin adhesive allergy which inhibits ongoing use of CGM
• chronic oral steroid use.

Diagnosis of gestational diabetes during current pregnancy, age 18 or older, and prescribed Dexcom G7

Identifying dates